51
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Current trends and challenges in cancer management and therapy using designer nanomaterials

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nanotechnology has the potential to circumvent several drawbacks of conventional therapeutic formulations. In fact, significant strides have been made towards the application of engineered nanomaterials for the treatment of cancer with high specificity, sensitivity and efficacy. Tailor-made nanomaterials functionalized with specific ligands can target cancer cells in a predictable manner and deliver encapsulated payloads effectively. Moreover, nanomaterials can also be designed for increased drug loading, improved half-life in the body, controlled release, and selective distribution by modifying their composition, size, morphology, and surface chemistry. To date, polymeric nanomaterials, metallic nanoparticles, carbon-based materials, liposomes, and dendrimers have been developed as smart drug delivery systems for cancer treatment, demonstrating enhanced pharmacokinetic and pharmacodynamic profiles over conventional formulations due to their nanoscale size and unique physicochemical characteristics. The data present in the literature suggest that nanotechnology will provide next-generation platforms for cancer management and anticancer therapy. Therefore, in this critical review, we summarize a range of nanomaterials which are currently being employed for anticancer therapies and discuss the fundamental role of their physicochemical properties in cancer management. We further elaborate on the topical progress made to date toward nanomaterial engineering for cancer therapy, including current strategies for drug targeting and release for efficient cancer administration. We also discuss issues of nanotoxicity, which is an often-neglected feature of nanotechnology. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field.

          Related collections

          Most cited references235

          • Record: found
          • Abstract: not found
          • Article: not found

          Gold nanoparticles in chemical and biological sensing.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Progress and challenges towards targeted delivery of cancer therapeutics

            Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Liposomes as nanomedical devices

              Since their discovery in the 1960s, liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for their biological and technological advantages, and are considered to be the most successful drug-carrier system known to date. Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be put on the market, or have already been approved for public use. In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, surface charge, and lipidic organization. Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ability to enter tissues, and final fate in vivo. Finally, we describe some strategies developed to overcome limitations of the “first-generation” liposomes, and liposome-based drugs on the market and in clinical trials.
                Bookmark

                Author and article information

                Contributors
                +91 9620160336 , navyapn@sit.ac.in
                +91 8884774863 , +91 8764402136 , hemant.daima@sit.ac.in , hkdaima@jpr.amity.edu
                Journal
                Nano Converg
                Nano Converg
                Nano Convergence
                Springer Singapore (Singapore )
                2196-5404
                15 July 2019
                15 July 2019
                December 2019
                : 6
                : 23
                Affiliations
                [1 ]ISNI 0000 0004 0501 2828, GRID grid.444321.4, Nano-Bio Interfacial Research Laboratory (NBIRL), Department of Biotechnology, , Siddaganga Institute of Technology, ; Tumkur, Karnataka 572103 India
                [2 ]ISNI 0000 0001 2179 088X, GRID grid.1008.9, Melbourne Integrative Genomics, School of BioSciences/School of Mathematics and Statistics, , The University of Melbourne, ; Melbourne, VIC 3010 Australia
                [3 ]ISNI 0000 0001 0790 959X, GRID grid.411377.7, School of Optometry, , Indiana University, ; Bloomington, Indiana 47405 USA
                [4 ]ISNI 0000 0001 2163 3550, GRID grid.1017.7, Centre for Advanced Materials and Industrial Chemistry, School of Science, , RMIT University, ; Melbourne, VIC 3001 Australia
                [5 ]ISNI 0000 0001 2184 9220, GRID grid.266683.f, Department of Chemistry, , University of Massachusetts (UMass) Amherst, ; 710 North Pleasant Street, Amherst, MA 01003 USA
                [6 ]ISNI 0000 0004 1805 0217, GRID grid.444644.2, Amity Institute of Biotechnology, , Amity University Rajasthan, ; Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, Rajasthan 303002 India
                [7 ]ISNI 0000 0001 0613 6919, GRID grid.252262.3, Department of Biotechnology, , Bannari Amman Institute of Technology, ; Sathyamangalam, Erode, Tamil Nadu 638401 India
                Author information
                http://orcid.org/0000-0001-9345-8253
                http://orcid.org/0000-0002-9109-430X
                Article
                193
                10.1186/s40580-019-0193-2
                6626766
                31304563
                1328efa3-da68-4b25-b2d4-abea51bad93a
                © The Author(s) 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 7 May 2019
                : 17 June 2019
                Categories
                Review
                Custom metadata
                © The Author(s) 2019

                drug delivery,cancer therapy,engineered nanomaterials,next-generation,nanotoxicity

                Comments

                Comment on this article